May 4, 2021 07:18 AM EDTUpdated 03:45 PM

Covid-19 roundup: EMA begins rolling review of first Chinese vaccine; After 100% efficacy trial, teenagers could be eligible for Pfizer's vaccine next week

Josh Sullivan

Nicole DeFeudis

Editor

Sinovac’s shot — which was just effective enough to meet regulatory standards — is now the first Chinese Covid-19 vaccine to be considered by the European Medicines …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: EMA begins rolling review of first Chinese vaccine; After 100% efficacy trial, teenagers could be eligible for Pfizer's vaccine next week

Josh Sullivan

Nicole DeFeudis

Editor

Sign up to read this article for free.

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Covid-19 roundup: EMA be­gins rolling re­view of first Chi­nese vac­cine; Af­ter 100% ef­fi­ca­cy tri­al, teenagers could be el­i­gi­ble for Pfiz­er's vac­cine next week

Editor

Sign up to read this article for free.

Covid-19 roundup: EMA begins rolling review of first Chinese vaccine; After 100% efficacy trial, teenagers could be eligible for Pfizer's vaccine next week